Delpazolid

An oxazolidinone antibiotic

Delpazolid
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Delpazolid is an investigational antibiotic belonging to the oxazolidinone class. It is being developed for the treatment of tuberculosis and other bacterial infections.

Mechanism of Action

Delpazolid works by inhibiting bacterial protein synthesis. It binds to the 50S subunit of the bacterial ribosome, thereby preventing the formation of the 70S initiation complex, which is essential for bacterial translation. This mechanism is similar to that of other oxazolidinones, such as linezolid.

Pharmacokinetics

Delpazolid is administered orally and has been shown to have good bioavailability. It is metabolized in the liver and excreted primarily through the kidneys. The pharmacokinetic profile of delpazolid supports its use in treating systemic infections, as it achieves therapeutic concentrations in the blood and tissues.

Clinical Development

Delpazolid is currently undergoing clinical trials to evaluate its efficacy and safety in treating multidrug-resistant tuberculosis (MDR-TB) and other serious bacterial infections. Early studies have shown promising results, with delpazolid demonstrating activity against a range of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE).

Potential Benefits

The development of delpazolid is particularly important in the context of increasing antibiotic resistance. As a new member of the oxazolidinone class, delpazolid offers a potential alternative for treating infections that are resistant to existing antibiotics. Its oral formulation also provides an advantage in terms of ease of administration compared to intravenous antibiotics.

Safety and Tolerability

In clinical trials, delpazolid has been generally well-tolerated. Common side effects include gastrointestinal disturbances, such as nausea and diarrhea. As with other oxazolidinones, there is a potential risk of myelosuppression, particularly with prolonged use. Monitoring of blood counts is recommended during treatment.

Related Pages

• Oxazolidinone
• Linezolid
• Antibiotic resistance
• Tuberculosis